OS Therapies (OSTX) said Monday it has formed OS Drug Conjugates unit and initiated a review of strategic options for its tunable antibody-drug conjugates and other tunable drug conjugates platforms.
The biotechnology company said it has started talks with antibody-drug conjugates therapeutics companies in the US, China, and other jurisdictions for potential joint ventures that will be spun off into standalone public companies.
Shares of the company rose more than 8% in recent Monday premarket activity.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。